Related Experiment Video

Updated: Mar 26, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

Elena Viziteu1, Camille Grandmougin1, Hartmut Goldschmidt2,3

  • 1Institute of Human Genetics, CNRS-UPR1142, Montpellier F-34396, France.

British Journal of Cancer
|February 12, 2016
PubMed
Abstract

Insights

Chetomin, a HIF-1α/p300 inhibitor, shows anti-cancer effects in multiple myeloma (MM). This compound may benefit MM patients with high EP300/HIF-1α expression and poor prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is a fatal plasma cell cancer.
  • Constitutive hypoxia-inducible factor 1-alpha (HIF-1α) expression in MM indicates HIF-1α-mediated transcription as a potential therapeutic target.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the HIF-1α/p300 interaction in multiple myeloma.

Main Methods:

  • Disruption of the HIF-1α/p300 co-activator complex to inhibit HIF transcriptional activity.
  • Utilizing chetomin, a known inhibitor of the HIF-1α/p300 interaction.

Main Results:

  • Chetomin demonstrated significant anti-tumour activity.
  • This activity was observed in both human myeloma cell lines and primary MM cells from patients.

Conclusions:

  • Chetomin exhibits potential clinical value for treating multiple myeloma.
  • It may be particularly effective for patients with high EP300/HIF-1α expression and a poor prognosis.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
34
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
40